🧪 Theranostics Newsletter | 02.2025 Edition

Here’s your latest dose of Theranostic Insights—a curated snapshot of what’s new and next in the world of theranostics powered by TheranosticTrials.org. From clinical breakthroughs to tech trends, we’ve got the highlights you need to stay ahead.

Latest Theranostics News 📰

Dosimetry Emerges as Key to Optimizing Lu-177 Cancer Therapy
Personalized dosimetry is gaining traction as a critical factor in improving outcomes with radiopharmaceuticals like lutetium-177 (Lu-177) PSMA-617. Experts note that modern tools now allow clinicians to precisely measure uptake in tumors and healthy tissues, enabling more tailored treatments. However, widespread adoption still faces challenges in standardization and workflow integration. Continue reading here.

ASCO GU 2025: PSMA PET/CT Proposed as New Standard for Assessing Prostate Cancer Response
At ASCO GU 2025, Dr. Danny M. Cortes highlighted the need to move beyond conventional imaging when evaluating response to radioligand therapy in prostate cancer. He presented RECIP 1.0, a new criterion based on PSMA PET/CT that assesses tumor volume changes and new lesion development. This method offers a more accurate picture of treatment effectiveness and could lead to smarter, more timely clinical decisions. Incorporating PSMA PET/CT and dosimetry into trials may significantly enhance personalized prostate cancer care. Continue reading here.

New PET Tracer Targets Triple-Negative Breast Cancer with High Accuracy
Researchers at Fudan University Shanghai Cancer Center have developed a promising new PET radiotracer that targets Nectin-4, a protein highly expressed in triple-negative breast cancer (TNBC). The tracer demonstrated strong sensitivity and specificity in early studies, offering a noninvasive way to detect and monitor this aggressive cancer subtype. This innovation could open the door to more effective Nectin-4-targeted therapies and personalized treatment strategies for TNBC patients. Continue reading here.

Radiopharmaceutical Trends to Watch in 2025
The radiopharmaceutical industry is poised for significant advances in 2025, with innovations in radiochemistry and targeted therapies leading the way. This Forbes Council article highlights trends such as precision imaging, novel therapeutic isotopes, and streamlined regulatory pathways reshaping the field. Companies must also tackle supply chain and infrastructure challenges to scale effectively as demand grows. Continue reading here.

Plus Therapeutics Advances Rhenium-186 Obisbemeda for Leptomeningeal Metastases
Plus Therapeutics has completed its ReSPECT-LM Phase 1 single-dose escalation trial, identifying 44.1 mCi of Rhenium-186 Obisbemeda as the recommended Phase 2 dose (RP2D) for treating leptomeningeal metastases. The dose showed strong tolerability with no observed toxicities and led to a complete response in one patient. The company will now advance both a Phase 2 single-dose expansion and a multiple-dose Phase 1 trial. Continue reading here.

Eckert & Ziegler and Bicycle Therapeutics Forge Strategic Radiopharmaceutical Partnership
Eckert & Ziegler has announced a new strategic alliance with Bicycle Therapeutics to supply radioisotopes and manufacture Bicycle’s proprietary Bicycle® Radio Conjugates (BRC®) for upcoming clinical trials. The collaboration pairs Eckert & Ziegler’s GMP manufacturing capabilities with Bicycle’s novel bicyclic peptide platform, aiming to expand access to hard-to-reach therapeutic targets and address critical unmet medical needs. This partnership marks a significant step toward advancing next-generation radiopharmaceuticals for cancer and beyond. Continue reading here.